Ves v 1
Summary
Ves v 1 is a marker allergen for genuine sensitization to Vespula vulgaris (common wasp or yellow jacket) venom (YJV). The sensitization rate to Ves v 1 in YJV allergic patients varies from 9 to 79%. In patients sensitized to both YJV and honeybee venom (HBV) extracts, demonstration of Ves v 1-specific IgE confirms genuine sensitization to YJV, helps to differentiate true double positivity to YJV and HBV from cross-reactivity, and to identify adequate venom immunotherapy (VIT) in eligible patients. Ves v 1 is a phospholipase A1 (PLA1) with a molecular weight of 34 kDa. Ves v 1 cross-reactivity with Pol d 1 precludes its use for discrimination between YJV and Polistes dominula (European paper wasp) venom sensitization.
Epidemiology
Worldwide distribution
The prevalence of Ves v 1 sensitization depends on the population that is considered: 9-79% in YJV allergic patients [1-3], 60-70% of subjects with detectable IgE to YJV extract [4], 21-30% of asymptomatic adult subjects having experienced at least one Hymenoptera sting [4, 5]. In the paediatric general population, Ves v 1 sensitization is infrequent, as demonstrated in a recent serologic study conducted in nine European birth cohorts [6].
Clinical Relevance
Specific molecules
Ves v 1 is a marker allergen of genuine sensitization to Vespid venom [1]. Ves v 1 sensitization can be demonstrated in YJV allergic patients without detectable Ves v 5 sensitization [2, 4]. The combined use of Ves v 5 and Ves v 1 for the diagnosis of YJV sensitization achieves a high diagnostic sensitivity of 90% or higher, yet fails to identify 2-8% of confirmed YJV allergic patients [1, 9, 10].
Ves v 1 does not cross-react with phospholipases of the PLA2 family found in HBV, therefore, Ves v 1 is a marker allergen allowing to discriminate between HBV and Vespid venom sensitization [1].
Cross-reactive molecules
Other PLA1 venom allergens, exhibiting variable degrees of sequence identity and serological cross-reactivity with Ves v 1, have been characterized in wasp, hornet and ant venoms, but not in HBV [1, 7]. Ves v 1 does not allow discrimination between YJV and PWV sensitization [1].
Disease severity
Neither the prevalence of Ves v 1 sensitization, nor the levels of Ves v 1-specific IgE are predictive of the severity of YJV-induced reactions [1, 3].
Diagnostics
Diagnosis of genuine sensitization to Vespula vulgaris (yellow jacket wasp) venom
Ves v 1 is a marker allergen for genuine YJV sensitization. Therefore, the demonstration of specific IgE to Ves v 1 confirms genuine sensitization to YJV, helps identifying the primary sensitizer in patients with double IgE positivity to HBV and YJV extracts, and supports the initiation of YJV VIT in eligible patients [1].
Conversely, as nearly all patients who are primarily sensitized to YJV test positive to Ves v 5 and/or Ves v 1, a patient who tests negative to both Ves v 5 and Ves v 1 is unlikely to have primary YJV sensitization, regardless of IgE to other YJV components [1].
Cross-Reactivity
Cross-reactivity within the PLA1 family and the lack of availability of other PLA1 allergens for routine diagnosis hamper Ves v 1 use for the differential diagnosis of YJV versus PWV genuine sensitization. No marker allergen is currently available for proper differentiation of Vespula versus Polistes genuine sensitization in routine assays [1]. However, it has been suggested that the relative amount of specific IgE to distinct PLA1 allergens, or the use of CAP inhibition assays, might help identifying the primary venom sensitizer [1].
Disease severity
In Hymenoptera venom IgE testing, the quantitative result of specific IgE to a molecular allergen or whole venom extract is neither predictive of, nor correlated to the severity of the reaction [1].
Sensitivity of in vitro assays
The prevalence of sensitization to individual YJV allergens, including Ves v 1, in YJV-allergic patients varies depending on multiple factors such as geography, patient inclusion criteria, single or double positivity to YJV and other Hymenoptera venoms, the use of a recombinant allergen from bacterial or insect cell expression versus a natural purified allergen, assay format, and positivity cut-off values [1, 4, 13]. Thus, the diagnostic sensitivity of specific IgE to Ves v 1 ranges from 9 to 79% in YJV-allergic patients [1-3, 5, 13]. The choice of the cut-off value for reporting detectable Ves v 1-specific IgE, usually debated between 0.35 kUA/L and 0.1 kUA/L, leads to important variations, up to two-fold, in the prevalence and therefore the analytical sensitivity of the test [5, 10]. Using a lower cut-off improves the diagnostic sensitivity and has been proposed in patients with mast cell disorders [10]. The EAACI 2023 guidelines suggest that the 0.10 kUA/L cut-off might be clinically relevant even in patients without mast cell disorders [1].
Detectable Ves v 1 sensitization has been reported in confirmed YJV allergic patients without detectable sensitization to YJV extract [4]. This rare occurrence has become exceptional, from 4.5% to 0.3% of YJV-negative sera, since the spiking of YJV extract with antigen 5 has improved the detection performance of the YJV extract [4].
Ves v 1 sensitization can be detected with commercially available singleplex and multiplex methods.
Diagnostic specificity
Detection of Ves v 1-specific IgE is a hallmark of genuine sensitization to Vespid venom, exhibiting a diagnostic specificity of 94-100% in this case [3, 14]. However, Vespid venom sensitization is not synonymous with Vespid venom allergy. The prevalence of YJV and therefore of Ves v 1 sensitization among asymptomatic subjects in the general population explains the lack of diagnostic specificity of Ves v 1 as a screening test in this context [1, 5]. Finally, Ves v 1 sensitization in YJV allergic patients does not differ between those with systemic reactions to YJV stings (eligible for YJV VIT) and those without systemic reactions [1, 3, 5].
AIT Prescription
Demonstrated sensitization to Ves v 1 confirms genuine sensitization to YJV in patients with a convincing clinical history, thus supporting the choice of YJV VIT in eligible patients [1].
Cross-Reactivity
Ves v 1 has high cross-reactivity with Pol d 1 preventing discrimination between Vespula vulgaris (common wasp) and Polistes dominula (European paper wasp) venom sensitization [1].
Isoforms, epitopes, antibodies
As of August 13, 2023, a unique isoallergen, Ves v 1.0101, has been included in the World Health Organization (WHO) and International Union of Immunological Societies (IUIS) Allergen Nomenclature [12].
Cross-reactivity due to structural similarity
Cross-reactivity between PLA1 allergens from Vespid and ant venoms is limited due to relatively low sequence identity percentages (30% - 77%) and to variations in the tertiary structure [1, 7].
Explained Results
Allergen Information
Ves v 1 is a PLA1 with a molecular weight of 34 kDa that exerts IgE-dependent and IgE-independent effects. It is produced by the yellow jacket (common wasp) Vespula vulgaris and secreted into the venom, where it represents 6 – 14% of the dry weight.
Clinical information
Ves v 1 is a marker allergen for YJV genuine sensitization, reported as a major allergen in YJV allergic patients although its prevalence may vary from 9 to 79% as a function of the cohort. HBV lack Ves v 1 homologues. Thus, Ves v 1-specific IgE identifies genuine Vespid sensitization and discriminates it from HBV sensitization in patients who are double positive to YJV and HBV extracts.
Cross-reactivity
Ves v 1 has variable cross-reactivity with PLA1 allergens from other wasps, hornets and ants, thus preventing its use for the discrimination between Vespula vulgaris and Polistes dominula venom sensitization.
Author: Dr. Joana Vitte
Reviewer: Dr. Michael Spangfort
1. Dramburg S, Hilger C, Santos AF, de Las Vecillas L, Aalberse RC, Acevedo N, et al. EAACI Molecular Allergology User's Guide 2.0. Pediatr Allergy Immunol. 2023;34 Suppl 28:e13854.
2. Seismann H, Blank S, Cifuentes L, Braren I, Bredehorst R, Grunwald T, et al. Recombinant phospholipase A1 (Ves v 1) from yellow jacket venom for improved diagnosis of hymenoptera venom hypersensitivity. Clin Mol Allergy. 2010;8:7.
3. Kukkonen AK, Pelkonen AS, Edelman SM, Kauppi PM, Makela MJ. Component-resolved diagnosis in selecting patients for yellowjacket venom immunotherapy. Ann Allergy Asthma Immunol. 2018;120:184-9.
4. Lambert C, Birnbaum J, Dzviga C, Hutt N, Apoil P, Bienvenu F, et al. Antigen 5-spiked Vespula and Polistes venom extracts for Vespid allergy diagnostics: A French multicenter study. Annals of Allergy Asthma & Immunology. 2018;120:435-7.
5. Zink A, Schuster B, Winkler J, Eyerich K, Darsow U, Brockow K, et al. Allergy and sensitization to Hymenoptera venoms in unreferred adults with a high risk of sting exposure. World Allergy Organ J. 2019;12:100039.
6. Kiewiet MBG, Lupinek C, Vrtala S, Wieser S, Baar A, Kiss R, et al. A molecular sensitization map of European children reveals exposome- and climate-dependent sensitization profiles. Allergy. 2023;78:2007-18.
7. Perez-Riverol A, Lasa AM, Dos Santos-Pinto JRA, Palma MS. Insect venom phospholipases A1 and A2: Roles in the envenoming process and allergy. Insect Biochem Mol Biol. 2019;105:10-24.
8. Elieh Ali Komi D, Shafaghat F, Zwiener RD. Immunology of Bee Venom. Clin Rev Allergy Immunol. 2018;54:386-96.
9. Vos B, Köhler J, Müller S, Stretz E, Ruëff F, Jakob T. Spiking venom with rVes v 5 improves sensitivity of IgE detection in patients with allergy to Vespula venom. J Allergy Clin Immunol. 2013;131:1225-7, 7.
10. Michel J, Brockow K, Darsow U, Ring J, Schmidt-Weber CB, Grunwald T, et al. Added sensitivity of component-resolved diagnosis in hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis. Allergy. 2016;71:651-60.
11. UniProt. UniProt P49369 for Ves v 1 2023 [Available from: https://www.uniprot.org/uniprotkb/P49369/entry.
12. IUIS/WHO. Vespula vulgaris 2023 [Available from: http://allergen.org/search.php?allergenname=&allergensource=Vespula+vulgaris&TaxSource=&TaxOrder=&foodallerg=all&bioname=.
13. Sturm GJ, Kranzelbinder B, Schuster C, Sturm EM, Bokanovic D, Vollmann J, et al. Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare. J Allergy Clin Immunol. 2014;133:1635-43.
14. Schrautzer C, Bokanovic D, Hemmer W, Lang R, Hawranek T, Schwarz I, et al. Sensitivity and specificity of Hymenoptera allergen components depend on the diagnostic assay employed. J Allergy Clin Immunol. 2016;137:1603-5.